Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland (S.L.D., C.L.P., M.F., L.L.); Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (S.L.D.); Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark (M.A.H., B.H.); Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse (C.L.P., G.F.K., L.F.V.) and Medication Development Program, National Institute on Drug Abuse Intramural Research Program (A.S., K.C.R., L.L.), National Institutes of Health, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health (M.F.) and Division of Addiction Medicine, Department of Medicine, School of Medicine (L.L.), Johns Hopkins University, Baltimore, Maryland; Department of Chemistry (J.E.M., J.L.H.), Department of Biology (J.L.H.), and BioInspired Syracuse (J.L.H.), Syracuse University, Syracuse, New York; Pfizer Inc. Medicine Design, Groton, Connecticut (I.A.S.); Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (S.A., F.A.); Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (A.S., K.C.R.); and Center for Alcohol Addiction Studies, Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, Rhode Island (L.L.)